Antero Kallio
Chief Executive Officer at BIOTIE THERAPIES CORP
Network origin in Antero Kallio first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 31 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Antero Kallio via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| FRESENIUS SE & CO. KGAA | Medical Specialties | Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ACORDA THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder General Counsel Corporate Officer/Principal | |
Zeneus Pharma Ltd.
 Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Medical Distributors | Comptroller/Controller/Auditor | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director of Finance/CFO | |
elbion NV
 elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Pharmaceuticals: Major | Founder Director of Finance/CFO Director/Board Member | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Biotie Therapies AG
 Biotie Therapies AG Pharmaceuticals: MajorHealth Technology Part of Acorda Therapeutics, Inc., Biotie Therapies AG is a holding company that focuses on developing drugs for the treatment of psychiatry and neurology diseases. The company is based in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Investment Managers | Chief Executive Officer Corporate Officer/Principal | |
| UCB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| MEDIGENE AG | Biotechnology | Chief Executive Officer | |
| University of Oxford | College/University | Doctorate Degree Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Graduate Degree | |
Roche Palo Alto LLC
 Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Toronto | College/University | Undergraduate Degree Doctorate Degree | |
| SCIBASE HOLDING AB (PUBL) | Medical Specialties | Director/Board Member | |
| ENDOCYTE, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Technical University of Berlin | College/University | Doctorate Degree Doctorate Degree | |
| Aalto University | College/University | Graduate Degree Graduate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
New York Biotechnology Association, Inc.
 New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| ATHERSYS, INC. | Biotechnology | Chairman Chairman | |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member Chairman | |
Okairos SRL
 Okairos SRL Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Okairos SRL is an Italian company that manufactures drugs. The company is based in Rome, Italy. | Pharmaceuticals: Major | Chairman Director/Board Member | |
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Biotechnology | President | |
Astex Pharmaceuticals, Inc.
 Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded in March 1991 and is headquartered in Pleasanton, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Laurantis Pharma Oy
 Laurantis Pharma Oy Pharmaceuticals: MajorHealth Technology Laurantis Pharma Oy engages in the development of pharmaceutical products. The company was founded in July 2008 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Versant EuroVentures | Chairman Chief Executive Officer | ||
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Biotechnology | Chairman | |
| Scibase AB | Director/Board Member | ||
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Acorda Therapeutics Ltd.
 Acorda Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Acorda Therapeutics Ltd. operates as a biopharmaceutical company. It manufactures pharmaceutical preparations and performs research and experimental development. The company was incorporated on March 03, 2009 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer President | |
| INFLARX N.V. | Biotechnology | Director of Finance/CFO | |
Jazz Pharmaceuticals France Holdings SAS
 Jazz Pharmaceuticals France Holdings SAS Financial ConglomeratesFinance Jazz Pharmaceuticals France Holdings SAS is a biopharmaceutical company that develops medicines. The company is headquartered in Lyon, France. | Financial Conglomerates | Corporate Officer/Principal | |
| Bluehaven Therapeutics AG | Chief Executive Officer |
Statistics
International
| United States | 17 |
| Germany | 9 |
| United Kingdom | 8 |
| Switzerland | 7 |
| Belgium | 4 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 9 |
| Commercial Services | 4 |
| Finance | 3 |
| Distribution Services | 2 |
Operational
| Director/Board Member | 236 |
| Corporate Officer/Principal | 85 |
| Chairman | 73 |
| Independent Dir/Board Member | 59 |
| Chief Executive Officer | 33 |
Most connected contacts
| Insiders | |
|---|---|
| Andrew Schwab | 45 |
| Bradley Bolzon | 41 |
| Mahendra Shah | 35 |
| William Burns | 27 |
| Ismail Kola | 26 |
| Ann Hanham | 26 |
| James Shannon | 23 |
| Guido Magni | 23 |
| Peter John Fellner | 21 |
| Krish S. Krishnan | 19 |
| Thomas Taapken | 16 |
| Don Bailey | 15 |
| Christoph Schröder | 14 |
| Jane Wasman | 14 |
| Timo Ilari Veromaa | 12 |
- Stock Market
- Insiders
- Antero Kallio
- Company connections
